It belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists
Two independent controlled studies using the same dose concluded the effect was of little clinical significance and not likely to be of major therapeutic benefit. Because the negative studies matched the positive studies dose, the failure cannot be explained by underdosing
Downstream Signaling Pathways When these molecular interactions occur, a number of downstream signaling pathways become involved in experimental systems
By understanding its pharmacokinetic profile, accounting for influencing factors, and sourcing only the highest quality product, you're laying a robust foundation for meaningful scientific discovery
[DOI] [PubMed] [Google Scholar] 5.Arciero PJ, Gardner AW, Calles-Escandon J, Benowitz NL, Poehlman ET